Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diabetes mellitus is a group of chronic metabolic diseases characterized by sustained high blood glucose due to defects in insulin secretion, insulin action, or both[5][7]. It encompasses several types, including type 1 diabetes, type 2 diabetes, gestational diabetes mellitus, and rare forms such as monogenic diabetes. Diabetes is conventionally defined by elevated plasma glucose and hemoglobin A1c, and it is diagnosed according to specific clinical criteria[5]. The disease is managed by lifestyle, pharmacological interventions, and sometimes insulin replacement therapy, depending on the underlying pathophysiology[1][6]. Novel therapies for diabetes target underlying molecular mechanisms, such as insulin receptors, sodium-glucose cotransporter 2 (SGLT2), dipeptidyl peptidase-4 (DPP-4), and glucagon-like peptide-1 (GLP-1) receptor[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diabetes.